Therapy News and Research

RSS

Addition of physical activity intervention to usual care does not reduce depressive symptoms

Current clinical guidance recommends physical activity to alleviate the symptoms of depression. However, new research published in the BMJ, suggests that adding a physical activity intervention to usual care did not reduce symptoms of depression more than usual care alone, even though it increased levels of physical activity.

16 Jun 2012

St. Michael's to investigate new treatments for prevention of brain injury complications

St. Michael's Hospital has been awarded up to $700,000 from the Federal Economic Development Agency of Southern Ontario to investigate new treatments to prevent complications following certain brain injuries.

16 Jun 2012

Prevena Incision Management System may help decrease incidence of groin SSIs

Kinetic Concepts, Inc. announced today that evidence presented at the Society for Vascular Surgery Conference in Washington, D.C. on June 8, 2012 suggests the Prevena™ Incision Management System, when combined with standard perioperative infection prevention and meticulous surgical technique, may help decrease the incidence of groin surgical site infections (SSIs) in patients undergoing vascular procedures.

16 Jun 2012

Civitas commences CVT-301 Phase 2a trial in Parkinson's disease

Civitas Therapeutics, Inc., a privately-held pharmaceutical company developing transformative therapeutics using the ARCUS respiratory delivery platform, announced today the initiation of a Phase 2a clinical trial in Parkinson's disease patients evaluating CVT-301, an inhaled formulation of levodopa (L-dopa), for the rapid relief from motor fluctuations.

16 Jun 2012

Roundup: Iowa redesign of mental health services raises concerns; Mich. lawmakers opposed to abortion restrictions are 'silenced'

State leaders hope their mental health redesign will bring better services to (rural areas of Iowa), but many front-line administrators doubt they'll see significant improvements soon. In fact, some worry that services could erode over the next year as money and some financial responsibilities are shifted from the counties to the state. Some long-term improvements are possible, they say, but cash likely will run short in the next few months.

15 Jun 2012

Drug shows promise as skin cancer treatment

A new drug for a type of skin cancer caused by a rare genetic disease can not only substantially shrink the tumors, but can also prevent the growth of new cancers, US investigators have discovered.

15 Jun 2012

Long-term rhythm, not rate, control may prolong life with AF

Rhythm control therapy for atrial fibrillation may improve survival rates compared with rate control therapy when used long term, show study results published in the Archives of Internal Medicine.

15 Jun 2012

Advances in robotic spine surgery

1. Please could you give a brief outline of robotic spine surgery and its recent history? Robotic spine surgery is very new, less than 10 years old. There are only 10 hospitals in the US offering it and we are the second hospital in California to offer this technology.

15 Jun 2012

Sanofi’s insulin glargine delays progression from pre-diabetes to T2DM

Sanofi presented results from the landmark ORIGIN trial (Outcome Reduction with Initial Glargine Intervention) at the American Diabetes Association 72nd Scientific sessions. The key findings showed that, compared to standard care, Lantus(insulin glargine [rDNA] injection) had no statistically significant positive or negative impact on cardiovascular (CV) outcomes versus standard care during the study period and that there was no association between insulin glargine use and increased risk of any cancer.

15 Jun 2012

The Healing Group launches Hey Mom! campaign

The Healing Group, a Salt Lake City-based women's wellness center, today announced the launch of its Hey Mom! campaign, designed to raise awareness, offer support and reduce the stigma commonly associated with postpartum depression (PPD) and related disorders.

15 Jun 2012

ISCO develops new TTF-based stem cell technology

International Stem Cell Corporation announced that scientists in its wholly-owned subsidiary, Lifeline Cell Technology (LCT), have developed a technology to modify human stem cells by using engineered proteins, called "transducible transcription factors" or "TTFs."

15 Jun 2012

DFINE completes initial phase of STAR Tumor Ablation System trial

DFINE, Inc., the developer of minimally invasive radiofrequency (RF) targeted therapies for the treatment of vertebral pathologies, today announced an upcoming poster presentation at the World Congress of Interventional Oncology (WCIO), June 14-18 in Chicago.

15 Jun 2012

Positive results from Salutaris’ episcleral brachytherapy trial on Wet AMD

Positive results from a trial of episcleral brachytherapy to treat Wet Age-related Macular Degeneration (Wet AMD) were presented today at the ARVO Drug and Gene Delivery to the Back of the Eye Conference.

15 Jun 2012

Osiris receives consent from NZ to market Prochymal for GvHD

Osiris Therapeutics, Inc., announced today it has received consent from New Zealand to market its first-in-class stem cell therapy Prochymal (remestemcel-L), for the treatment of acute graft-vs-host disease (GvHD) in children.

15 Jun 2012

FDA clears KCI’s V.A.C.Therapy System

Kinetic Concepts, Inc. announced today that it has received 510(k) clearance from the Food and Drug Administration (FDA) to market its proprietary Vacuum Assisted Closure, or V.A.C. Therapy System, for the management of closed surgical incisions.

15 Jun 2012

Study reveals molecular link between aging and cancer

It has long been known that cancer is a disease of aging, but a molecular link between the two has remained elusive.

15 Jun 2012

Sanovas receives U.S. patent allowance for microsurgical lung cancer technology

Sanovas, Inc., a medical technology company focused on developing and commercializing next-generation micro-invasive diagnostics, devices and drug delivery technologies, today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office for its first patent relating to systems and methods for the removal of unwanted biological material, such as tissue growths and tumors, in hard-to-reach bodily cavities.

15 Jun 2012

Study strengthens link between HHV-6B and mesial temporal lobe epilepsy

A ten-year NIH-funded study has determined that a third of infants with prolonged seizures and fever suffer from either a new or reactivated roseola virus infection. Roseola viruses are the cause of the common childhood rash, but can also cause limbic encephalitis, a condition that frequently progresses to epilepsy. Investigators discovered one of the roseola viruses, human herpesvirus-6B (HHV-6B) in the blood of 32% of 169 infants with prolonged seizures, a condition known as status epilepticus.

15 Jun 2012

High-efficiency oxygen inhaler from Dehaier

Dehaier Medical Systems Ltd., an emerging leader in the development, assembly, marketing and sale of medical devices and homecare medical products in China, today announced that the Company has co-developed its "High-Efficiency Oxygen Inhaler" with Dr. Ding Jianzhang of Beijing Haidian Hospital, which is expected to begin selling in the third quarter of 2012 in mainland China.

15 Jun 2012

Quest receives FDA clearance to initiate oregovomab Phase II trial in ovarian cancer

Quest PharmaTech Inc., a pharmaceutical company developing and commercializing products for the treatment of cancer, announces that it has received clearance from the United States Food and Drug Administration to initiate U.S. sites for an ongoing international Phase II clinical trial for oregovomab in advanced ovarian cancer patients.

15 Jun 2012